Resumen

CANAS, Martín; BUSCHIAZZO, Héctor Omar  y  URTASUN, Martín Alejandro. Therapeutic value and price of the new pharmaceuticals commercialized in Argentina: Are they worth what they cost?. Salud colect. [online]. 2019, vol.15, e1962. ISSN 1669-2381.  http://dx.doi.org/10.18294/sc.2019.1962.

In Argentina, new drugs can be authorized by presenting the drug’s certificate of approval in at least one of 15 countries considered to have rigorous health surveillance, without needing to carry out a local evaluation of the efficacy, safety or added therapeutic value of the new product. In this article, we evaluate the new drugs commercialized in Argentina in 2016 using different approaches: their approval by other regulatory agencies, the demonstration of their efficacy in randomized clinical trials, types of outcomes studied, rating of their added therapeutic value using two widely recognized scales, and their sale price to the public. It is concluded that, as a reflection of what occurs in developed countries, new drugs enter the market at exorbitant prices, but the majority do not represent a significant therapeutic advancements. The result is increased risks to patients and an overburdening of the public and private funding systems.

Palabras clave : Drug Approval; Drug Evaluation; Drug Costs; Argentina.

        · resumen en Español     · texto en Español | Inglés     · Español ( pdf ) | Inglés ( pdf )